JP6755175B2 - インスリン投薬レジメン - Google Patents

インスリン投薬レジメン Download PDF

Info

Publication number
JP6755175B2
JP6755175B2 JP2016503654A JP2016503654A JP6755175B2 JP 6755175 B2 JP6755175 B2 JP 6755175B2 JP 2016503654 A JP2016503654 A JP 2016503654A JP 2016503654 A JP2016503654 A JP 2016503654A JP 6755175 B2 JP6755175 B2 JP 6755175B2
Authority
JP
Japan
Prior art keywords
insulin
long
acting insulin
insulin analog
acting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016503654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516076A (ja
JP2016516076A5 (enExample
Inventor
トゥエ・ヨハンセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2016516076A publication Critical patent/JP2016516076A/ja
Publication of JP2016516076A5 publication Critical patent/JP2016516076A5/ja
Application granted granted Critical
Publication of JP6755175B2 publication Critical patent/JP6755175B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016503654A 2013-03-20 2014-03-19 インスリン投薬レジメン Expired - Fee Related JP6755175B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13160194.0 2013-03-20
EP13160194 2013-03-20
US201361804363P 2013-03-22 2013-03-22
US61/804,363 2013-03-22
PCT/EP2014/055533 WO2014147141A1 (en) 2013-03-20 2014-03-19 Insulin dosing regimen

Publications (3)

Publication Number Publication Date
JP2016516076A JP2016516076A (ja) 2016-06-02
JP2016516076A5 JP2016516076A5 (enExample) 2017-04-27
JP6755175B2 true JP6755175B2 (ja) 2020-09-16

Family

ID=47900938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503654A Expired - Fee Related JP6755175B2 (ja) 2013-03-20 2014-03-19 インスリン投薬レジメン

Country Status (5)

Country Link
US (4) US20160296602A1 (enExample)
EP (1) EP2976096B1 (enExample)
JP (1) JP6755175B2 (enExample)
CN (1) CN105188736A (enExample)
WO (1) WO2014147141A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
EP3544683A1 (en) 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
MA46890A (fr) * 2016-11-28 2021-04-28 Novo Nordisk As Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
AU2018216008A1 (en) 2017-02-01 2019-08-01 Novo Nordisk A/S Procoagulant antibodies
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
AR112015A1 (es) 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
CN112313755B (zh) * 2018-06-26 2024-05-28 诺和诺德股份有限公司 为基础胰岛素滴定提供剂量推荐的系统
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
TW202039437A (zh) 2018-12-11 2020-11-01 法商賽諾菲公司 肽黏合劑
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261353B2 (en) * 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
ES2472421T3 (es) * 2003-08-05 2014-07-01 Novo Nordisk A/S Nuevos derivados de insulina
EP1969004B1 (en) * 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
CN101454019A (zh) * 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
WO2009022006A1 (en) * 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
CN102202683A (zh) * 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
AU2011252127B2 (en) * 2010-05-10 2014-02-20 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
KR20130139297A (ko) * 2010-10-27 2013-12-20 노보 노르디스크 에이/에스 다양한 주사 간격으로 투여된 인슐린 주사를 이용한 진성 당뇨병의 치료
AU2012213432B2 (en) * 2011-02-01 2016-10-13 Novo Nordisk A/S Purification of insulin
AU2012223282B2 (en) * 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
EP2844274B1 (en) * 2012-05-01 2019-03-20 Novo Nordisk A/S Pharmaceutical composition
EP2991672A1 (en) * 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime

Also Published As

Publication number Publication date
EP2976096B1 (en) 2019-02-27
CN105188736A (zh) 2015-12-23
US20190160155A1 (en) 2019-05-30
WO2014147141A1 (en) 2014-09-25
JP2016516076A (ja) 2016-06-02
US20160296602A1 (en) 2016-10-13
US20220152160A1 (en) 2022-05-19
US20170319664A1 (en) 2017-11-09
EP2976096A1 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
US20220152160A1 (en) Dosing regimen
JP4959005B2 (ja) 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
EP2632478B1 (en) Treating diabetes melitus using insulin injections administered with varying injection intervals
US10137172B2 (en) Administration regime
US20080213288A1 (en) Combined Use Of A Modulator Of CD3 And A GLP-1 Compound
EP1515749B1 (en) Combined use of a modulator of cd3 and a glp-1 compound
JP2013545782A (ja) 長時間作用型インスリンと組み合わせた速効型インスリン
KR102231074B1 (ko) 인슐린 글라진／릭시세나티드 고정비 제형
JP6262206B2 (ja) 医薬組成物
US10596229B2 (en) Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
HK1191551A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170321

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190403

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200825

R150 Certificate of patent or registration of utility model

Ref document number: 6755175

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees